118 related articles for article (PubMed ID: 21709690)
1. Diabetes and prostate cancer risk in the REDUCE trial.
Wu C; Moreira DM; Gerber L; Rittmaster RS; Andriole GL; Freedland SJ
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):326-31. PubMed ID: 21709690
[TBL] [Abstract][Full Text] [Related]
2. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
[TBL] [Abstract][Full Text] [Related]
3. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
[TBL] [Abstract][Full Text] [Related]
4. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.
Moreira DM; Anderson T; Gerber L; Thomas JA; Bañez LL; McKeever MG; Hoyo C; Grant D; Jayachandran J; Freedland SJ
Cancer Causes Control; 2011 Jul; 22(7):977-83. PubMed ID: 21562753
[TBL] [Abstract][Full Text] [Related]
5. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
Gong Z; Neuhouser ML; Goodman PJ; Albanes D; Chi C; Hsing AW; Lippman SM; Platz EA; Pollak MN; Thompson IM; Kristal AR
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1977-83. PubMed ID: 17035408
[TBL] [Abstract][Full Text] [Related]
6. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy.
Hong SK; Oh JJ; Byun SS; Hwang SI; Lee HJ; Choe G; Lee SE
Prostate; 2012 Jan; 72(1):51-7. PubMed ID: 21520162
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.
Thomas JA; Gerber L; Bañez LL; Moreira DM; Rittmaster RS; Andriole GL; Freedland SJ
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):576-81. PubMed ID: 22315364
[TBL] [Abstract][Full Text] [Related]
8. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
Freedland SJ; Terris MK; Platz EA; Presti JC
Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
[TBL] [Abstract][Full Text] [Related]
11. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.
Albisinni S; De Nunzio C; Tubaro A; Barry WT; Banez LL; Freedland SJ
Urology; 2012 Jul; 80(1):162-7. PubMed ID: 22608797
[TBL] [Abstract][Full Text] [Related]
12. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
13. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
14. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
15. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
[TBL] [Abstract][Full Text] [Related]
16. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
Freedland SJ; Platz EA; Presti JC; Aronson WJ; Amling CL; Kane CJ; Terris MK
J Urol; 2006 Feb; 175(2):500-4; discussion 504. PubMed ID: 16406980
[TBL] [Abstract][Full Text] [Related]
17. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR
J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
[TBL] [Abstract][Full Text] [Related]
18. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.
D'Amico AV; Braccioforte MH; Moran BJ; Chen MH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1329-37. PubMed ID: 19879061
[TBL] [Abstract][Full Text] [Related]
19. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer.
Rohrmann S; Roberts WW; Walsh PC; Platz EA
Prostate; 2003 May; 55(2):140-6. PubMed ID: 12661039
[TBL] [Abstract][Full Text] [Related]
20. Obesity and prostate enlargement in men with localized prostate cancer.
Kopp RP; Han M; Partin AW; Humphreys E; Freedland SJ; Parsons JK
BJU Int; 2011 Dec; 108(11):1750-5. PubMed ID: 21736693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
